Lucid issues recall of 69,000 bottles of antidepressant meds

Lucid Pharma issues recall of antidepressant drugs.

Lucid Pharma issued a nationwide voluntary recall of about 69,000 extended-release capsules of venlafaxine hydrochloride, which is used as an antidepressant.

The recall of the subscription-only drug was initiated by the company in early June, and was reported by the FDA this week. Included in the recall are 30-count and 90-count bottles.

The cause cited was failed tablet/capsule specification after pharmacists complained of bottles containing melted capsules.

The FDA listed the recall as a Class II event.

ACETO acquired Lucid and Citron Pharma late last year in a deal valued at about $412 million. 

New Jersey-based Lucid is a generic pharmaceutical distributor specializing in providing products to various agencies of the U.S. federal government, including the Department of Veterans Affairs and the Defense Logistics Agency.